The new system is said to combine remote monitoring with firm’s PaceWave Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy.
ResMed Europe and Asia Pacific president Anne Reiser said: "The launch of Air Solutions and the unique offering of the AirCurve 10 CS PaceWave with AirView represents a landmark shift in the treatment of central sleep apnoea.
"By combining ResMed-patented technology with new wireless monitoring capabilities, we are providing a solution that is both an effective therapy, and has potential to offer significant time and cost savings to physicians and health services."
Using the patented algorithm, PaceWave MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, providing an option to treat different patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing.
It is mostly suitable for patients suffering with Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly oserved in heart failure patients.
According to the firm, the use of PaceWave MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF randomised trial.
The study, which completed 1,325 patients enrolment in 2013, has been designed to investigate if treating chronic heart failure patients who also have CSA with PaceWave MV-ASV therapy may improve outcomes including mortality and morbidity.
Currently, AirCurve 10 CS PaceWave is available for customers in select European countries.
